Vol. 4 No. 1 (2024)
Reimbursement Reviews

Tremelimumab (Imjudo) in Combination With Durvalumab (Imfinzi)

decorative image of the issue cover

Published January 25, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses tremelimumab (Imjudo), 20 mg/mL, concentrate IV infusion in combination with durvalumab (Imfinzi), 50 mg/mL, concentrate for IV infusion.
  • Indication: Proposed: Imjudo (tremelimumab for injection) in combination with durvalumab is indicated for the first-line treatment of adult patients with unresectable hepatocellular carcinoma who require systemic therapy.